We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
35
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Completed
19
54.3%
Not yet recruiting
1
2.9%
Recruiting
14
40.0%
Withdrawn
No approval data available
- Lumosa Therapeutics' LT3001 demonstrated a robust safety profile and tolerability in a Phase II clinical trial for acute ischemic stroke patients. - The trial, conducted by Shanghai Pharma, showed comparable adverse event rates between LT3001 and placebo groups over 90 days. - Preliminary efficacy data indicated a promising proportion of patients achieving favorable outcomes on the modified Rankin Scale (mRS) at Day 90 post-treatment. - Lumosa plans to collaborate with Shanghai Pharma and seek international licensing to advance LT3001's global development for stroke treatment.
